Mitogen-activated protein kinase pathway kinase (MAPK pathway kinase)

The RAS-pathway kinases, primarily consisting of the RAF, MEK, and ERK protein kinase families, constitute the core of the mitogen-activated protein kinase (MAPK) signaling cascade (NIH, 2023). This pathway is a fundamental regulator of cellular processes such as proliferation, differentiation, and survival, acting as a bridge between cell surface receptors and nuclear transcription factors (UniProt, 2024). Mutations in pathway components, most notably RAS and BRAF, lead to constitutive activation and are found in approximately 30% of all human cancers, including melanoma, pancreatic, and colorectal carcinomas (PubMed, 2022). Therapeutic targeting of these kinases has led to the development of several FDA-approved inhibitors, such as vemurafenib and trametinib, which have significantly improved outcomes for patients with specific mutations like BRAF V600E (FDA, 2023). However, the clinical utility of these inhibitors is often limited by the emergence of resistance mechanisms and unique safety profiles, including the paradoxical activation of the pathway in non-mutated cells, which can promote the development of secondary malignancies (Nature Reviews Cancer, 2021). The term 'Unspecified RAS-pathway kinase' is a generic designation used when a specific member of this cascade is not identified.

Other names

RAS pathway kinaseERK pathway kinaseMAPK cascade kinaseRAS-RAF-MEK-ERK pathway kinaseRAS-MAPK pathway kinase

Inhibition of the kinase activity of components within the RAS-RAF-MEK-ERK signaling cascade, typically through ATP-competitive or allosteric binding, to suppress downstream signaling and inhibit oncogenic cell growth.